Why the study?
Does high-sensitivity C-reactive protein measurement help in cardiovascular risk stratification in patients with coronary heart disease?
Does high-sensitivity C-reactive protein measurement help in cardiovascular risk stratification in patients with coronary heart disease?
This review highlights the clinical utility of high-sensitivity C-reactive protein as a reliable biomarker for cardiovascular risk stratification and a potential therapeutic target in coronary heart disease.
May aid risk stratification in coronary heart disease; leaves open therapeutic targeting pending randomized trials.
High-sensitivity C-reactive protein levels have received widespread attention because of a multitude of prospective studies that have shown that high levels of high-sensitivity C-reactive protein identify increased risk of initial cardiovascular events in coronary heart disease patients and increased risk of recurrent cardiac events in patients with stable and unstable angina, patients with acute myocardial infarction, and patients undergoing elective coronary revascularization procedures. In contrast to several other inflammatory markers, high-sensitivity C-reactive protein measurements are standardized and reproducible. The clinical significance of a reliable inflammatory marker includes identification of high-risk individuals, a gauge to monitor the activity of the disease, and a potential therapeutic target to alter the inflammatory component of the disease process. This review focuses on the importance of high-sensitivity C-reactive protein in cardiovascular risk stratification in coronary heart disease patients and discusses several preventive therapies that may reduce cardiovascular risk through reduction in high-sensitivity C-reactive protein.
No takes yet. Share an insight, caveat, or question.
Rosenson et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: